初始化项目，由ModelHub XC社区提供模型

Model: vmal/med-advisor-conversation-4B
Source: Original Platform

examples/thinking/t10-predictive-vs-prognostic.md

@@ -0,0 +1,56 @@
+# Predictive versus prognostic biomarkers
+
+| Audience | Knowledge level | Intent | Topic | Mode | Turns |
+|---|---|---|---|---|---:|
+| Healthcare worker | Advanced | Explanation, mechanism and evidence | Oncology biomarkers, trial statistics | Thinking | 2 |
+
+**Highlights:** Technical definitions with real examples · Confirms and refines the user's framing · Adds two caveats unprompted
+
+---
+
+### Turn 1
+
+**User**
+
+> How does a predictive cancer biomarker differ from a prognostic biomarker?
+
+**Med Advisor**
+
+A **prognostic biomarker** estimates the likelihood of a clinical outcome—such as recurrence, survival, or progression—**regardless of the treatment** a patient receives. It helps predict who might do better or worse based on their biology. Examples include ER/PR/HER2 status in breast cancer, which can inform prognosis and treatment options, and certain genetic alterations that correlate with overall survival.
+
+A **predictive biomarker** estimates whether a specific treatment is likely to produce a benefit—**compared with another treatment or with no treatment**. It helps select the therapy that is expected to work best for that patient. Examples include EGFR mutations predicting response to EGFR-targeted therapy, PD-L1 expression predicting benefit from immunotherapy, and BRCA mutations predicting benefit from PARP inhibitors.
+
+Key distinction:
+- **Prognostic:** “What is likely to happen?”
+- **Predictive:** “Which treatment is likely to help?”
+
+A biomarker can sometimes serve both roles—for example, HER2 amplification is prognostic in some contexts and predictive of benefit from HER2-directed therapy. But a biomarker is not automatically predictive; it must be validated in a specific treatment context.
+
+In practice, both types are used to guide decisions, but predictive biomarkers are generally more directly tied to treatment selection, while prognostic biomarkers mainly inform prognosis and risk stratification.
+
+### Turn 2
+
+**User**
+
+> Got it—so the operative distinction is the treatment-by-biomarker interaction, right? Just to make it explicit: a purely prognostic marker shifts outcome the same way across arms, whereas a predictive one needs a differential treatment effect to hold up in validation. Is that the standard framing?
+
+**Med Advisor**
+
+Yes—that’s the standard framing.
+
+A **prognostic** biomarker is associated with the outcome **regardless of treatment**. It shifts risk or prognosis the same way across treatment arms. In a trial, it may help stratify patients or estimate baseline risk.
+
+A **predictive** biomarker is associated with a **differential treatment effect**—that is, the benefit of one treatment over another differs by biomarker status. The treatment-by-biomarker interaction is the operative distinction: prognostic markers don’t change how much a treatment helps; predictive markers do.
+
+Two refinements:
+
+- “Purely prognostic” is a useful ideal, but a biomarker can also be predictive and prognostic. HER2 status is a classic example.
+- A statistical interaction is not automatically clinically meaningful; validation requires showing the differential benefit holds up in a defined treatment context.
+
+So: prognostic = same outcome shift across arms; predictive = different treatment effect across arms.
+
+---
+
+[← T09](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t09-testicular-torsion-note.md) · [All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md)
+
+*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*